Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $980.00 Price Target at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by equities research analysts at TD Cowen from $960.00 to $980.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s target price suggests a potential upside of 21.76% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group increased their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Finally, Raymond James Financial boosted their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $846.28.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of Regeneron Pharmaceuticals stock traded down $2.60 on Wednesday, hitting $804.88. 202,661 shares of the company’s stock traded hands, compared to its average volume of 815,764. The company has a fifty day moving average of $791.41 and a two-hundred day moving average of $721.87. Regeneron Pharmaceuticals has a one year low of $572.75 and a one year high of $859.34. The company has a market capitalization of $82.87 billion, a price-to-earnings ratio of 19.87, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $12.81 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 47.98 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 in the last three months. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of REGN. Bell Bank bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $229,000. Nisa Investment Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 19,710 shares of the biopharmaceutical company’s stock worth $14,946,000 after acquiring an additional 298 shares during the last quarter. Capital Management Associates Inc bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $212,000. LCM Capital Management Inc lifted its position in Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares in the last quarter. Finally, Tred Avon Family Wealth LLC lifted its position in Regeneron Pharmaceuticals by 24.7% in the 3rd quarter. Tred Avon Family Wealth LLC now owns 662 shares of the biopharmaceutical company’s stock valued at $502,000 after acquiring an additional 131 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.